Literature DB >> 35121838

PAK4 as a cancer immune-evasion target.

Thomas F Gajewski1, Jessica Fessler2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 35121838     DOI： 10.1038/s43018-019-0012-z

Source DB:  PubMed          Journal:  Nat Cancer        ISSN： 2662-1347


× No keyword cloud information.
  2 in total

1.  Synthesis of selective PAK4 inhibitors for lung metastasis of lung cancer and melanoma cells.

Authors:  Peilu Song; Fan Zhao; Dahong Li; Jiqiang Qu; Miao Yao; Yuan Su; Hanxun Wang; Miaomiao Zhou; Yujie Wang; Yinli Gao; Feng Li; Dongmei Zhao; Fengjiao Zhang; Yu Rao; Mingyu Xia; Haitao Li; Jian Wang; Maosheng Cheng
Journal:  Acta Pharm Sin B       Date:  2022-03-04       Impact factor: 14.903

Review 2.  Recent advances on development of p21-activated kinase 4 inhibitors as anti-tumor agents.

Authors:  Yang Li; Qing Lu; Chenghu Xie; Yiming Yu; Ao Zhang
Journal:  Front Pharmacol       Date:  2022-08-29       Impact factor: 5.988
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.